Immunopathogenesis and Immunogenetic Variants in COVID-19

Area of Science:

• Immunology
• Genetics
• Virology

Background:

• Despite vaccine availability, Coronavirus disease 2019 (COVID-19) continues to spread globally, leading to severe complications like acute respiratory distress syndrome and cytokine storms.
• Immunopathology and immunogenetics are crucial for understanding, diagnosing, and treating severe COVID-19 and its associated cytokine storm.
• While many immune-related genetic variants have been studied, the roles of NOD-like receptor protein 3 (NLRP3) and interleukin 18 (IL-18) in COVID-19 clinical outcomes remain underexplored.

Purpose of the Study:

• To review the current understanding of COVID-19 immunopathogenesis and immunogenetic factors contributing to severe disease and cytokine storms.
• To construct and analyze protein-protein interaction (PPI) networks focusing on NLRP3 and IL-18 variants in severe COVID-19.
• To identify potential drug targets and predictive biomarkers for severe COVID-19 and associated cytokine storms.

Main Methods:

• Literature review on COVID-19 immunopathogenesis and immunogenetics.
• Construction and analysis of protein-protein interaction (PPI) networks using enrichment and annotation analysis.
• Focus on NLRP3 and IL-18 variants and their association with severe COVID-19.

Main Results:

• PPI network and enrichment analyses identified key antiviral pathways, including Toll-Like-Receptor cascades, NOD-like receptor signaling, and interferon signaling.
• Significant involvement of interleukins (IL-1, IL-6, IL-12, IL-18) and tumor necrosis factor signaling in severe COVID-19 pathophysiology was predicted.
• Innate immune evasion by SARS-CoV-2 and the roles of MYD88 and MAVS in severe COVID-19 were highlighted.

Conclusions:

• The study predicts potential drug targets for preventing severe COVID-19 by modulating identified antiviral and inflammatory pathways.
• Genetic variants within the constructed PPI network may serve as predictors for severe COVID-19 outcomes.
• Targeted preventive treatments can be developed based on these predictive markers and identified therapeutic targets.